NCT04514367View on ClinicalTrials.gov

An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 17, 2020

Primary Completion Date

January 28, 2022

Study Completion Date

January 28, 2022

Conditions
Huntington Disease
Interventions
DRUG

ANX005

Intravenous Infusion

Trial Locations (6)

20057

Annexon Investigational Site 04, Washington D.C.

27710

Annexon Investigational Site 07, Durham

35294

Annexon Investigational Site 02, Birmingham

45221

Annexon Investigational Site 06, Cincinnati

80113

Annexon Investigational Site 03, Englewood

98034

Annexon Investigational Site 08, Kirkland

All Listed Sponsors
lead

Annexon, Inc.

INDUSTRY

NCT04514367 - An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease | Biotech Hunter | Biotech Hunter